3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
4
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
382
Carboplatin
279
Specimen Handling
266
Nivolumab
256
Magnetic Resonance Spectroscopy
247
Cyclophosphamide
242
Cisplatin
217
Paclitaxel
208
Radiotherapy
196
Biopsy
171
Gemcitabine
158
Dexamethasone
149
durvalumab
148
atezolizumab
128
Rituximab
123
Doxorubicin
117
Bevacizumab
115
Ipilimumab
114
Lenalidomide
113
Radiation
111
Pemetrexed
104
Docetaxel
104
Etoposide
102
venetoclax
98
fludarabine
97
Radiosurgery
94
Capecitabine
94
Fluorouracil
93
Oxaliplatin
91
Prednisone
90
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Histamine H2 Antagonists
×
1 year
×
Clear all
NCT06305754
2026-05-29
MK-2870-009
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
520 enrolled